Statin dose in Asians: Is pharmacogenetics relevant?

Pharmacogenomics

Volumn 12, Issue 11, 2011, Pages 1605-1615

  Wang, Ping ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Asians; dose; pharmacogenetics; statin

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABCG8 PROTEIN; ATORVASTATIN; ATP BINDING CASSETTE SUBFAMILY G MEMBER 8; BREAST CANCER RESISTANCE PROTEIN; CERIVASTATIN; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KINESIN; KINESIN FAMILY MEMBER 6; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VITAMIN D;

ABC TRANSPORTER A1 GENE; ABC TRANSPORTER GENE; ABCG2 GENE; ABCG8 GENE; ALLELE; ASIAN; ATP BINDING CASSETTE SUBFAMILY G MEMBER 8 GENE; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CYTOCHROME P450 3A4 GENE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; ETHNICITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENOTYPE; HMGCR GENE; HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE GENE; KINESIN FAMILY MEMBER 6 GENE; LEPTIN RECEPTOR GENE; MYALGIA; MYOPATHY; ORGANIC ANION TRANSPORTER 2 GENE; PHARMACOGENETICS; RECOMMENDED DRUG DOSE; REVIEW; SLCO1B1 GENE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, PHARMACOLOGICAL; BODY MASS INDEX; BODY WEIGHT; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 80455131311     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.98     Document Type: Review

References (103)

1. Kim HS, Wu Y, Lin SJ et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr. Med. Res. Opin. 24(7), 1951-1963 (2008).
2. Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J. Clin. Pharmacy Therap. 30(1), 21-37 (2005).
3. Tan CE, Loh LM, Tai ES. Do Singapore patients require lower doses of statins? The SGH lipid clinic experience. Singapore Med. J. 44(12), 635-638 (2003).
4. Gupta M, Braga MF, Teoh H, Tsigoulis M, Verma S. Statin effects on LDL and HDL cholesterol in South Asian and white populations. J. Clin. Pharmacol. 49(7), 831-837 (2009).
5. Morales D, Chung N, Zhu JR et al. Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies. Curr. Med. Res. Opin. 20(8), 1235-1243 (2004).
6. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Cardiol. 22(11), 913-927 (2006).
7. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol. 54(5), 472-477 (2002).
8. Sekino H, Onishi T. Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor-evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J. Clin. Ther. Med. 21, 187-203 (2005).
9. Warwick M, Dane A, Raza A, Schneck DW. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 151(1), 39 (2000).
10. Lee E, Ryan S, Birmingham B et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Therap. 78(4), 330-341 (2005).
11. Tzeng TB, Schneck DW, Birmingham BK et al. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr. Med. Res. Opin. 24(9), 2575-2585 (2008).
12. Tan AT, Low LP, Lim CH, Tan CE. Effects of rosuvastatin on low-density lipoprotein cholesterol and plasma lipids in Asian patients with hypercholesterolemia. J. Atheroscleros. Thrombosis 16(4), 509-516 (2009).
13. Muck W, Unger S, Kawano K, Ahr G. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br. J. Clin. Pharmacol. 45(6), 583-590 (1998).
14. Martin PD, Warwick MJ, Dane AL et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Therap. 25(11), 2822-2835 (2003).
15. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Therap. 83(2), 251-257 (2008).
16. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276(38), 35669-35675 (2001).
17. Nishizato Y, Ieiri I, Suzuki H et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Therap. 73(6), 554-565 (2003).
18. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Therap. 80(4), 356-366 (2006).
19. Niemi M, Schaeffeler E, Lang T et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14(7), 429-440 (2004).
20. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogen. Genom. 16(12), 873-879 (2006).
21. Deng JW, Song IS, Shin HJ et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogen. Genom. 18(5), 424-433 (2008).
22. Chung JY, Cho JY, Yu KS et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Therap. 78(4), 342-350 (2005).
23. Ieiri I, Suwannakul S, Maeda K et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Therap. 82(5), 541-547 (2007).
24. Ho RH, Choi L, Lee W et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogen. Genom. 17(8), 647-656 (2007).
25. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Therap. 82(6), 726-733 (2007).
26. Tirona RG. Ethnic differences in statin disposition. Clin. Pharmacol. Therap. 78(4), 311-316 (2005).
27. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 10(1), 1-11 (2010).
28. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
29. Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. College Cardiol. 54(17), 1609-1616 (2009).
30. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Therap. 87(1), 130-133 (2011).
31. Fiegenbaum M, da Silveira FR, van der Sand CR et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Therap. 78(5), 551-558 (2005).
32. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogen. Genom. 17(9), 695-707 (2007).
33. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metabol. Pharmacokinet. 19(6), 453-455 (2004).
34. Furihata T, Satoh N, Ohishi T et al. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T≥G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogen. J. 9(3), 185-193 (2009).
35. Ishikawa C, Ozaki H, Nakajima T et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J. Hum. Genet. 49(10), 582-585 (2004).
36. Ahmed W, Khan N, Glueck CJ et al. Low serum 25 (OH) vitamin D levels (
37. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency - a novel mechanism of statin-induced myalgia? Clin. Endocrinol. 71(1), 154-155 (2009).
38. Goldstein MR. Myopathy, statins, and vitamin D deficiency. Am. J. Cardiol. 100(8), 1328 (2007).
39. Perez-Castrillon JL, Vega G, Abad L et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am. J. Cardiol. 99(7), 903-905 (2007).
40. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin. Pharmacol. Therap. 85(2), 198-203 (2009).
41. Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogen. J. 5(6), 352-358 (2005).
42. Li Y, Sabatine MS, Tong CH et al. Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Hum. Genet. 129(1), 17-23 (2011).
43. Shiffman D, Sabatine MS, Louie JZ et al. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Am. J. Cardiol. 105(9), 1300-1305 (2010).
44. Iakoubova OA, Tong CH, Rowland CM et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. College Cardiol. 51(4), 435-443 (2008).
45. Iakoubova OA, Sabatine MS, Rowland CM et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. College Cardiol. 51(4), 449-455 (2008).
46. Iakoubova OA, Robertson M, Tong CH et al. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur. J. Cardiovasc. Prev. Rehabil. 17(4), 455-461.
47. Ridker PM, Macfadyen JG, Glynn RJ, Chasman DI. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ. Cardiol. Genet. 4(3), 312-317 (2011).
48. Hu M, Lui SS, Mak VW et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogen. Genomics 20(10), 634-637 (2010).
49. Chien KL, Wang KC, Chen YC et al. Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics 11(3), 309-317 (2010).
50. Tachibana-Iimori R, Tabara Y, Kusuhara H et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metabol. Pharmacokinet. 19(5), 375-380 (2004).
51. Zhang W, Chen BL, Ozdemir V et al. SLCO1B1 521T-≥C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol. 64(3), 346-352 (2007).
52. Takane H, Miyata M, Burioka N et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J. Human Genet. 51(9), 822-826 (2006).
53. Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Intl J. Clin. Pharmacol. Therap. 48(1), 36-45 (2010).
54. Yang GP, Yuan H, Tang B et al. Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol. Sinica 31(3), 382-386 (2010).
55. Wang A, Yu BN, Luo CH et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Pharmacol. 60(12), 843-848 (2005).
56. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur. J. Clin. Pharmacol. 64(9), 877-882 (2008).
57. Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J. Clin. Pharmacol. 51(2), 181-188 (2011).
58. Sun YM, Wang LF, Li J, Li ZQ, Pan W. The 223A≥G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease. Eur. J. Clin. Pharmacol. 65(2), 157-161 (2009).
59. Li J, Wang LF, Li ZQ, Pan W. Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease. Clin. Experi. Pharmacol. Physiol. 36(5-6), 567-570 (2009).
60. Niemi M, Neuvonen PJ, Hofmann U et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype*17. Pharmacogen. Genom. 15(5), 303-309 (2005).
61. Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res. 55(4), 310-317 (2007).
62. Kivisto KT, Niemi M, Schaeffeler E et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14(8), 523-525 (2004).
63. Donnelly LA, Doney AS, Dannfald J et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes, a GoDARTS study. Pharmacogen. Genom. 18(12), 1021-1026 (2008).
64. Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117(12), 1537-1544 (2008).
65. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291(23), 2821-2827 (2004).
66. Noriega V, Pennanen C, Sanchez MP et al. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients. Basic Clin. Pharmacol. Toxicol. 104(3), 211-215 (2009).
67. Medina MW, Krauss RM. The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc. Med. 19(5), 173-177 (2009).
68. Donnelly LA, Palmer CN, Whitley AL et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogen. Genom. 18(4), 279-287 (2008).
69. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113(2), 157-166 (1995).
70. Guzman EC, Hirata MH, Quintao EC, Hirata RD. Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin. Chem. Lab. Med. 38(8), 731-736 (2000).
71. Salazar LA, Hirata MH, Quintao EC, Hirata RD. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J. Clin. Lab. Anal. 14(3), 125-131 (2000).
72. Maitland-van der Zee AH, Stricker BH, Klungel OH et al. Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis 175(2), 377-379 (2004).
73. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The Regression Growth Evaluation Statin Study Group. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N. Engl. J. Med. 338(2), 86-93 (1998).
74. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193(2), 438-444 (2007).
75. Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 103(6), 792-798 (2001).
76. Kirchheiner J, Kudlicz D, Meisel C et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Therap. 74(2), 186-194 (2003).
77. Itoh T, Matsumoto M, Hougaku H et al. The Simvastatin Study Group. Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. Clin. Therap. 19(3), 487-497 (1997).
78. Thuraisingham S, Tan KH, Chong KS, Yap SF, Pasamanikam K. A randomised comparison of simvastatin versus simvastatin and low cholesterol diet in the treatment of hypercholesterolaemia. Intl J. Clin. Practice 54(2), 78-84 (2000).
79. Chung N, Cho SY, Choi DH et al. STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target. Clin. Therap. 23(6), 858-870 (2001).
80. Wang KY, Ting CT. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jap. Heart J. 42(6), 725-738 (2001).
81. Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol - a multinational, multicenter, double-blind study. J. Formos. Med. Assoc. 101(7), 478-487 (2002).
82. Matsuzaki M, Kita T, Mabuchi H et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ. J. 66(12), 1087-1095 (2002).
83. Mabuchi H, Kita T, Matsuzaki M et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ. J. 66(12), 1096-1100 (2002).
84. Saito Y, Goto Y, Dane A, Strutt K, Raza A. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J. Atheroscler. Thromb. 10(6), 329-336 (2003).
85. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am. J. Cardiol. 94(2), 157-161 (2004).
86. Mabuchi H, Nohara A, Higashikata T et al. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J. Atheroscler. Thromb. 11(3), 152-158 (2004).
87. Patel JV, Gupta S, Lie F, Hughes EA. Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study. Vasc. Health Risk Manag. 1(4), 351-356 (2005).
88. Zhu JR, Tomlinson B, Ro YM, Sim KH, Lee YT, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr. Med. Res. Opinion. 23(12), 3055-3068 (2007).
89. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am. J. Cardiol. 99(11), 1538-1543 (2007).
90. Oikawa S, Kita T, Mabuchi H et al. Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis 191(2), 440-446 (2007).
91. Itakura H, Kita T, Mabuchi H et al. Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy: long-term efficacy and safety in Japanese patients with hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study, a prospective large-scale observational cohort study. Circ. J. 72(8), 1218-1224 (2008).
92. Takayama T, Hiro T, Yamagishi M et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ. J. 73(11), 2110-2117 (2009).
93. Tomlinson B, Hu M, Lee VW et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther. 87(5), 558-562 (2010).
94. Kim SR, Saito Y, Sai K et al. Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than*15. Drug Metabol. Pharmacokinet. 22(6), 456-461 (2007).
95. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9(1), 19-33 (2008).
96. Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug metabolism and disposition: Biol. Fate Chem. 29(9), 1205-1209 (2001).
97. Bienertova-Vasku JA, Spinarova L, Bienert P, Vasku A. Association between variants in the genes for leptin, leptin receptor, and proopiomelanocortin with chronic heart failure in the Czech population. Heart Vessels 24(2), 131-137 (2009).
98. Kim KA, Joo HJ, Park JY. ABCG2 polymorphisms, 34G≥A and 421C≥A in a Korean population: analysis and a comprehensive comparison with other populations. J. Clin. Pharm. Therap. 35(6), 705-712 (2010).
99. Zamber CP, Lamba JK, Yasuda K et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13(1), 19-28 (2003).
100. De Jong FA, Marsh S, Mathijssen RH et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10(17), 5889-5894 (2004).
101. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Intl J. Cancer. 109(2), 238-246 (2004).
102. PharmGKB www.pharmgkb.org
103. NCBI dbSNP www.ncbi.nlm.nih.gov/projects/SNP/snp-ref.cgi?rs=20455